Publications by authors named "K Mellgren"
Objectives: Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL.
View Article and Find Full Text PDFArticle Synopsis
- Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a diverse and challenging type of cancer that often has poor outcomes, especially in younger patients lacking the SMARCB1 protein.
- Research indicated that human and mouse PTCL-NOS exhibit similar DNA changes, including the hypermethylation of T-cell genes and the hypomethylation of myeloid development genes, contributing to a complicated tumor ecosystem.
- A study found that histone deacetylase inhibitors (HDACi), like SAHA, can effectively treat PTCL-NOS by modifying the tumor's microenvironment and improving immune function, paving the way for potential combination therapies.
Cytomegalovirus (CMV) infection, which mostly causes a subclinical infection early in life, has important clinical consequences in certain patient groups. CMV is the most common congenital infection and can cause permanent disabilities such as hearing loss and motor- and cognitive deficits in affected infants. In allogeneic haematopoietic stem cell and solid organ transplant recipients, CMV still is an important infectious complication with a risk for life-threatening disease.
View Article and Find Full Text PDFArticle Synopsis
- The purpose of the study was to understand how kids in the hospital, who had a tube put in for feeding, experience mealtime with their parents.
- The study talked to 21 families about the challenges they faced, like bad hospital food and other difficult situations during meals.
- The researchers found that using a feeding tube helped make mealtime better for kids, even though the hospital and food made eating harder.
Aims: Individuals with congenital heart disease (CHD) are at an increased risk for cancer. As cancer survival rates improve, the prevalence of late side effects, such as heart failure (HF), is becoming more evident. This study aims to evaluate the risk of developing HF following a cancer diagnosis in patients with CHD, compared with those without CHD and with CHD patients who do not have cancer.
View Article and Find Full Text PDF